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Abstract
Background: X-linked hypophosphataemia (XLH) is a rare, hereditary, progressive and lifelong phosphate wasting
disorder characterised by pathological elevations in fibroblast growth factor (FGF) 23 concentration and activity;
XLH has an incidence of approximately 1 in 20–25,000 individuals. Excess FGF23 activity leads to increased
phosphate excretion in the kidneys – mediated by downregulation of renal tubular phosphate transporters – and
reduced phosphate absorption in the intestines – due to impaired vitamin D activation. This results in impaired
bone growth and mineralisation, short and disproportionate stature, leg bowing, musculoskeletal pain, spontaneous
dental abscesses, rickets, and osteomalacia. The spectrum of manifestations differs between paediatric and adult
patients. Those involved in the treatment of this condition face many challenges, including a lack of robust natural
history and demographic data. This multicentre, international, rare-disease patient registry (XLH Registry) was
established to address the paucity of data in XLH and to help inform future clinical practice.
Results: The XLH Registry collects standard diagnostic and monitoring practice data, including (where applicable)
diagnosis and disease progression history, treatment regimens and family history; the protocol does not mandate
any interventions or clinical assessments. The XLH Registry aims to recruit 1200 paediatric and adult patients with
XLH over 10 years, and several data analyses and peer-reviewed publications are expected to be generated
throughout this period. A post-authorisation safety study for Bburosumab, for which the registry Sponsor is the
marketing authorisation holder, will be nested as a sub-study within the XLH Registry via a subsequent protocol
amendment.
Conclusion: The data collected within this rare-disease patient registry will be utilised to synthesise real-world
evidence to inform the management of XLH, to improve the quality of life and standard of care of patients living
with this rare debilitating disease.
Keywords: X-linked hypophosphataemia (XLH), Rare disease, Patient registry, Vitamin D, Disease history, Post-
authorisation safety, Bburosumab, Real-world evidence, Quality of life, XLH management
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Introduction
X-linked hypophosphataemia (XLH) is a rare, hereditary,
progressive and lifelong phosphate wasting disorder
characterised by pathological elevations in the serum
concentrations and activity of fibroblast growth factor
(FGF) 23. This increase in FGF23 is caused by inactivat-
ing mutations in the phosphate regulating endopeptidase
homolog, X-linked (PHEX) gene [1]. The exact mecha-
nisms linking PHEX and FGF23 remain to be fully eluci-
dated. However, PHEX mutations are thought to affect
expression, rather than degradation of FGF23 [2–4]. In-
creased FGF23 activity is responsible for downregulation
of the sodium-dependent phosphate co-transporters
NPT2a and NPT2c in the proximal renal tubules, along-
side diminished synthesis and increased catabolism of
active vitamin D due to decreased 1α-hydroxylase and
increased 24-hydroxylase enzyme activity. The combin-
ation of these physiological changes results in increased
phosphate wasting via the kidneys and reduced phos-
phate absorption in the intestines; these impairments in
phosphate homeostasis lead to chronic hypophosphatae-
mia [1]. Chronic hypophosphataemia is responsible for
both defective bone mineralisation and tooth formation,
leading to the typical skeletal and extra-skeletal manifes-
tations of XLH [1]. XLH affects around 1 in 20–25,000
individuals, meeting the European Union (EU) definition
of a rare-disease (affects < 1 in 2000 individuals) [5–8].
Patients affected by XLH display a diverse range of
signs, symptoms and diagnoses, which differ not only be-
tween paediatric and adult patients but also between af-
fected individuals. Circulating phosphate is integral for
optimal growth and mineralisation of newly formed
bones; paediatric patients are particularly affected as
these impairments in bone growth, and mineralisation
are often compounded during periods of rapid growth,
such as seen during childhood and adolescence. Chil-
dren with XLH typically present with symptoms such as
progressive bowing of weight-bearing extremities, de-
layed motor development, impaired and disproportional
growth, rickets, and future dental complications. Adults
with XLH often display symptoms and signs of osteo-
malacia such as excessive pain, pseudofractures and
osteoarthritis, alongside hearing deficits, increasing num-
bers of dental complications and abscesses over time,
musculoskeletal deficiencies such as stiffness, impaired
mobility, weakness and fatigue [9–11]. Many XLH com-
plications seen in adult patients are thought to stem
from sub-optimal disease management during childhood
[9–11]. All patients, regardless of age, tend to highlight
that their condition has a severe negative impact on
their quality of life [1, 10, 12]. Evidence from a recent
study by Skrinar et al. assessed the lifelong effects of
XLH on patients, finding that many symptoms of XLH
which emerge in the paediatric period remain unresolved,
and continue to impact patients during adulthood [11].
Both paediatric and adult patients, in the study by Skrinar
et al., reported substantially worse quality of life than the
general population [11]. Hence, findings from our study
highlight the need for a greater understanding of the nat-
ural history and disease progression profiles of patients
with XLH in order to improve the clinical management of
the condition.
Initially, the standard of care for patients with XLH
was the administration of very high doses of vitamin D;
the adjuvant use of phosphate salts was subsequently
published in 1964 [13, 14]. Today’s conventional treat-
ment of XLH – popularised in the late 1970s – involves
the administration of a combination of oral phosphate
and active vitamin D analogue(s) [9, 10], accompanied in
some cases by the use of adjuvant therapeutic options
such as growth hormone [9]. None of these treatments
have undergone regulatory scrutiny and/or approval,
suggesting there is no agreed posology, leading to differ-
ences between treatment regimens at national – and
even regional – levels; an extensive consensus document
on the diagnosis and management of XLH has recently
been published which aims to address these issues [9].
While these therapeutic regimens have demonstrated
improvements in the clinical manifestations of many pa-
tients, they only target phosphate and active vitamin D
deficiencies and not the disease-causing excess of FGF23
[9, 10]. Conventional therapy may also lead to iatrogenic
complications, such as tertiary hyperparathyroidism,
which may require additional therapeutic interventions,
such as parathyroidectomy or cinacalcet therapy [15].
Further, there has, until recently, been a lack of consen-
sus on the value of conventional treatment in adult pa-
tients. Newer guidelines recommend treatment only of
symptomatic adult patients, i.e. those with musculoskeletal
pain, pseudofractures, dental issues, planned orthopaedic
or dental surgery, or biochemical evidence of osteomal-
acia; the value of treatment in non-symptomatic adults
with XLH remains unclear [9, 10].
Recently, a biological treatment – the fully human
IgG1 monoclonal antibody (mAb) against FGF23, buro-
sumab – has received regulatory approval in Europe
(paediatric and adolescent patients only), the Middle-East,
South America, Canada and the USA for the treatment of
XLH [16, 17]. Existing evidence suggests burosumab may
be superior to conventional therapy, based on findings
from a Phase III clinical study in children with confirmed
rickets that have not responded adequately to conven-
tional therapy, with similar results observed in a Phase III
placebo-controlled study among symptomatic adults bur-
osumab [18, 19]. However, there currently remains a
dearth of data surrounding the long-term efficacy, safety
and drug usage information for burosumab in the broader
‘real-world’ population.
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Furthermore, as with many other rare diseases, there is
a limited availability of large-scale data reporting on the
epidemiology of XLH, particularly in terms of incidence,
prevalence, risk factors, co-morbidity, treatment modal-
ities and mortality on an international level. One of the
most effective methods of collecting all of the required
large-scale patient data – which has been effectively used
in other rare diseases – is the use of registries [20, 21].
Patient registries or disease registries, can either be
prospective, retrospective or a combination of prospect-
ive and retrospective observational cohort clinical stud-
ies, as no specific treatment, clinical assessment or data
collection are introduced or mandated as part of the
protocol [22]. Though patient registries can collect data
on particular treatments, they are exempt from the
European Commission’s (EC) Clinical Trials Regulation
as the protocol does not mandate any treatment or diag-
nostic and monitoring practices outside of standard clin-
ical practice [23]. The benefits of this choice of clinical
study are beginning to be realised – particularly in rare
diseases – not just by those involved in disease manage-
ment but also by regulatory bodies such as the European
Medicines Agency (EMA) [24–27]. Patient registries
allow for long-term assessment of patients with much
fewer exclusion criteria than typical clinical studies and
provide a wealth of disease-specific information.
The XLH patient registry is an international, multicen-
tre, non-interventional, observational cohort clinical
study of both paediatric and adult patients with XLH,
collecting data retrospectively at study entry and pro-
spectively during follow up. Expert centres for the treat-
ment of XLH across Europe and the Middle East were
invited to participate in the XLH Registry and the data
to be collected is intended to aid healthcare providers in
the optimisation of clinical decision making, through an
enhanced understanding of the variability, progression
and natural history of XLH, alongside the actual burden
of disease.
Methods
Registry identification
This rare-disease patient registry has been registered with
clinicaltrials.gov, under the identifier NCT03193476.
Study population
To be eligible for inclusion in the XLH Registry, patients
must meet all of the following criteria:
1. Male or female subjects of all ages at baseline.
2. Diagnosis of XLH with clinical, radiological,
biochemical and/or genetic findings consistent with
XLH.
Any patient meeting any of the following exclusion
criteria at baseline cannot be included in the XLH
Registry:
1. Patient or their legally designated representative
does not have the cognitive capacity to provide
informed consent.
2. Patients who are currently participating in an
interventional clinical trial.
a. Patients may be approached for inclusion in the
XLH Registry once their involvement in the
clinical trial (including all trial follow up
assessments) has been completed.
b. Participating in a Compassionate Use Program,
Pre-commercial Program (i.e. Named Patient
Sales, Nominative Temporary Use Authorisation
(TUA)) or Investigator-Initiated Study does not
preclude a patient from participation in the
XLH Registry.
Individuals who are treatment naïve, treated with con-
ventional therapy alone or in combination with adjuvant
therapies such as growth hormone or cinacalcet, treated
with burosumab, and those with prior XLH targeted
treatment histories but not currently receiving treatment
are all eligible for inclusion in the XLH Registry.
Study design
The XLH Registry is an international, multicentre, non-
interventional clinical study. It captures treatment details
and clinical outcome variables in patients with XLH and
patients are followed for as long as informed consent
(and assent, where applicable) and regulatory permis-
sions are maintained. Only data collected during stand-
ard routine examinations are recorded within the XLH
Registry, and no specific examinations/data entries are
mandated. Any drug therapy considered necessary for
the patients’ welfare may be administered at the discre-
tion of the treating physician; all such treatment and any
changes that occur throughout participation in the XLH
Registry are recorded in the database.
The XLH Registry was initiated in August 2017, gained
its first national regulatory approval in September 2017
(United Kingdom) and the first patient was enrolled on
the October 42,017. The XLH Registry will run for 10
years in the first instance, at which point the Sponsor
may decide to continue or discontinue the registry, in
agreement with the applicable regulatory authorities.
Registry objectives
The primary objective of the XLH Registry is to collect
data to characterise (where applicable) the treatment,
burden of disease, disease progression and long-term
outcomes of XLH in both paediatric and adult patients
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and assess the safety of medications used to manage the
symptoms and signs of XLH in both paediatric and adult
patients.
Determination of sample size
As this is a prospective, observational register of patients
with XLH, there is no specific sample size based on stat-
istical considerations. A survey conducted with XLH
clinical experts across Europe provided evidence sug-
gesting a total recruitment target of 1200 eligible XLH
patients would be appropriate to enable robust research
to be conducted on the data contained within the
Registry.
Ethics
The XLH Registry is run following the recommendations
from the Declaration of Helsinki and has received eth-
ical, regulatory and institutional approvals at national,
regional and site level for each participating country, as
required. Patient data held within the registry is kept in
accordance with the EU General Data Protection Regu-
lations (GDPR) on the processing of personal data and
the protection of privacy in the electronic communica-
tion sector (2016/679/EU).
All eligible patients with XLH visiting a participating
clinic are provided with the locally approved patient or
parental/caregiver information sheet to review. Age ap-
propriate information sheets have been developed for
those patients under the age of 18 (or 16) depending on
local guidelines.
Once a patient or their legal representative have
agreed to participate and provided informed consent,
they are enrolled in the XLH Registry; minors aged ≥12
years are also required to provide their assent before
study inclusion. Patient data is link-anonymised, with
physicians at the enrolling site retaining an enrolment
log to allow patient identification. No pre-determined
follow-up requirements apply for the XLH Registry.
However, physicians should update the registry promptly
after a patient’s visit, once new information is available
or, at a minimum, on an annual basis.
Participating centres were reimbursed for associated
registry activities including obtaining informed consent,
data entry and maintenance of regulatory folders.
Data collection
Determination of data and variables to collect
A systematic assessment of all clinical trials involving
patients with a diagnosis of XLH was performed to iden-
tify the clinical variables which should be included
within the registry. This initial list was then reviewed by
members of the steering committee, sponsoring organ-
isation, and service delivery team to determine whether
the identified variables should be included, formed part
of the standard diagnostic and monitoring practice at
participating centres and if, in their opinion, there were
any items which were missing and should be included as
part of the registry dataset. Following this appraisal, the
adjusted list was agreed upon by all members of the
steering committee and formed the finalised list of regis-
try data items.
Data to be collected
When patients are enrolled into the XLH Registry, both
retrospective data [past medical history] and data avail-
able at the time of consent [baseline visit] are collected.
Prospective data collected post-baseline at all routine
clinical visits will be added periodically (at least annu-
ally) to the database. As no investigations or data cap-
ture outside of routine clinical practice are mandated,
only information which is available to the treating phys-
ician within this framework is recorded within the XLH
Registry. The treating physician will also be responsible
for collecting information about compliance with previ-
ous XLH medications and drug history. The full list of
agreed potential data fields contained within the XLH
Registry is presented in Table 1, alongside a summary of
the time-points at which specific data is collected
(Table 2).
Data collection tools and data management
Registry data is collected in a purposely designed elec-
tronic case record form (eCRF) and data entered into
the registry is checked automatically using logical checks
(i.e. limits set within the database program). As the XLH
Registry does not mandate any investigations or assess-
ments, participating centres can include ‘not done’ infor-
mation to prevent missing data queries; this function
also serves as an assessment of standard of care regimes
across centres. If any confounding or missing data are
detected, an edit report is generated; the edit reports are
sent electronically to the sites for clarification.
Clinical trial data collected in studies conducted by the
Sponsor or affiliates will be used for data analysis along-
side the registry data, if the informed consent in these
studies allows for the data to be used for further re-
search purposes. The addition of previously collected pa-
tient data will strengthen the ability of the registry to
meet its primary objective.
Statistical methods
All patients enrolled in the registry are included in the
data analysis set. The Medical Dictionary for Regulatory
Activities (MDRA) will be used to code medical history,
and concomitant disease within the registry and registry
internal reports will incorporate information up to and
including the latest registry update for each patient. For
regular reports on the registry data, all continuous
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variables are described using standard statistical mea-
sures (i.e. number of observations, mean, standard devi-
ation, median, minimum and maximum). All categorical
data is summarised in frequency tables.
Patient disposition, demographic data and other base-
line characteristics are all treated as described above,
while laboratory measurements and other clinical data
are tabulated. Medications and medical histories are
coded according to the World Health Organisation Drug
Dictionary, before being summarised and tabulated.
Patient outcome measures and quality of life question-
naires will be summarised and listed.
Data quality assurance
Monitoring and auditing procedures
Registry sites are remotely monitored, and essential
registry and site documents are requested for both qual-
ity control and storage in the registry master file. Regis-
try sites are regularly contacted via telephone to assist
with registry activities and through remote monitoring
for queries.
Electronic Case record forms (eCRF)
The XLH Registry eCRF is completed and signed elec-
tronically for each included patient and is completed
only by individuals qualified and trained in the comple-
tion and data verification of the eCRF information. The
physician should ensure the accuracy, completeness, le-
gibility, and timeliness of the data reported in the eCRF.
All data requested must be recorded, and any missing
data must be explained. Any corrections will overwrite
the previous, initial information and an audit trail allow-
ing identification of any modifications will be main-
tained. Additional requests for confirming or modifying
questioned data may be generated through the eCRF,
and the investigator will be obliged to respond.
Management and reporting of adverse events/adverse
reactions
Details of adverse event reports associated with any
treatment for XLH submitted for an individual patient
in the previous year will be captured in the annual regis-
try entry for that patient. Adverse events will be coded
with the Medical Dictionary for Regulatory Activities
Table 2 Schedule of Assessments for Data Recording. Assessments in bold and italics are mandatory. All others are to be recorded
on an if completed basis
Assessments Study Visit
Retrospective Baseline Prospective
Site Characteristics X
Informed Consent (and/or assent, as applicable) a X Xa
Demographic information X
XLH-specific Physical Exam X
Medical history X X
PHEX mutationb X Xb
XLH medications X X X
Concomitant Medications X
Radiographs and imaging X X X
Physical examination (including dental and audiological assessments) X X X
Vital signs (e.g. heart rate, blood pressure) X X X
Growth assessments (e.g. Height, weight, head circumference) X X X
Physiotherapy X X X
Echocardiogram X X X
Electrocardiogram X X X
Audiology X X X
Renal ultrasound X X X
Patient assessment tools/outcome measures X X X
Exercise Tolerance Tests X
Patient Quality of Life questionnairesc X X X
Social Impact History X X X
aRe-consent to adult registry consent when patient transitions from paediatric to adult patient
bPHEX mutation to be recorded during prospective visit if not available during retrospective visit
cQuality of Life questionnaires used are dependent upon local clinical practices
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system and described by organ class. Cumulative adverse
event information will be reported in the registry’s in-
terim and final analyses.
Scientific steering committee
An international scientific committee consisting of ex-
perts on XLH has been established. This committee
consists of Sponsor representatives, European XLH phy-
sicians and experts in rare metabolic and endocrine
disorders, and European experts in patient registries.
Governance principles have been established describing
committee members’ responsibilities and obligations, as
well as the scientific oversight of the registry’s publica-
tion policy; further information adapted from the full
registry access agreement can be found below.
Physicians entering data into the registry will have
control of their centre’s aggregated data set, and both
they and their patients’ will be free to withdraw their
consent for their data to be used in analyses at any time;
ownership of evidence generated from the aggregated
data set will belong to the Sponsor. Access to anon-
ymised data held within the registry is available to all
research groups following a successful application to the
XLH Registry Steering Committee. The following three
steps must be completed as part of the request before
access to the anonymised data is provided:
1. Submission of a current access form, providing any
applicable supporting documentation,
2. Review of submitted access form and supporting
documentation by the XLH Registry Steering
Committee (six-week time limit),
3. Following a favourable outcome, applicants will
receive a signed letter from the XLH Registry
Steering Committee chair, alongside access to
anonymised registry data.
The results of all analyses approved by the Steering
Committee will be published by the responsible researchers
named on the successful access form, with acknowledge-
ment of the Sponsor and contributing investigator sites.
Registry reports are due to be written according to the
main objectives of the registry and will be authored in
collaboration with the XLH Registry Steering Commit-
tee; all statistical analyses performed within the study re-
ports must also be conducted under the supervision of
the Steering Committee.
Discussion
Within the field of rare diseases, patient registries can be
an invaluable source of natural history and epidemio-
logical, clinical and medical information which may
otherwise be unobtainable by traditional means [28].
Single centre – and even single country-level studies of
XLH are unlikely to be able to recruit a sufficient num-
ber of patients to allow for statistically robust conclu-
sions to be drawn from the collected data [8]. The
implementation and execution of a large, international
registry-based study may overcome the potential limita-
tions of smaller individual studies [29].
An area of continuing uncertainty in the management
of XLH is the appropriateness of treatment of adult
patients. While a recent consensus publication has pro-
vided some clarification on current treatment recom-
mendations in the adult XLH patient population,
treatment is recommended only in symptomatic adult
patients. A large-scale, long-term, patient registry col-
lecting treatment and outcomes data on adults may pro-
vide additional evidence that can be used to further
refine treatment approaches in this patient group [9].
Registry data may also provide an invaluable source of
data on adolescent patients transitioning into adult care;
this population is often mismanaged or lost to follow-up
care in many diseases, not just in XLH [30, 31].
Furthermore, a multi-national XLH patient registry
can collect real-world data not only on natural history
and patient demographics, but also on the effectiveness
and safety profiles of both conventional therapy and bur-
osumab. The collection of data from patients receiving
conventional treatment or burosumab alongside that of
patients who are not receiving treatment for XLH may
enable the assessment of risk-benefit profiles, informing
future clinical practice and improving the quality of care
for individuals suffering with XLH.
The XHL registry protocol was submitted for ethical
approval in all participating countries in August 2017,
and the first patient was recruited in October 2017
(Manchester, UK). As of December 2018, 176 patients
had been recruited into the registry out of a predicted
167 (105%); this correlates to 15% of the 1200 patient re-
cruitment target (Fig. 1a). A breakdown of recruitment
by country and region is shown in Fig. 1b.
Further to the registry protocol described, future work
includes the nesting of a Post-Authorisation Safety Study
(PASS) for burosumab as a sub-study within the over-
arching patient registry; regulators typically require a
PASS as part of the initial marketing authorisation of a
new medicinal product. The flexibility of the registry
protocol allows for protocol variations to be quickly
processed and implemented, and a full protocol will be
published shortly; not all XLH Registry sites are ex-
pected to participate in the PASS sub-study as this will
require the solicitation of adverse events, which may not
be within the capabilities of all participating sites.
Limitation
A fundamental limitation of this registry study relates to
the inconsistency between sites regarding the routine
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clinical monitoring data they collect. As the study is not a
clinical trial, other than informed consent and baseline
demographics, there is no mandatory data set which is re-
quired to be collected. To mitigate this limitation, work has
been conducted with the members of the Registry Steering
Committee to generate an XLH-specific Disease Severity
Score (DSS) which will form the basis of a Core Dataset.
This Core Dataset will help to standardise the information
being collected across all sites within the Registry; the DSS
will also be freely available to those involved in researching
or managing XLH.
Furthermore, we consider the limited applicability of
the FAIR (findability, accessibility, interoperability, and
reuse of digital assets) principles [32] in its entirety to
this clinical study on XLH, a potential limitation. This is
due to existing data protection and confidentiality re-
strictions on the utilisation and sharing of patient-level
data. While patient-level data will not be publicly avail-
able, evidence generated from aggregated data from the
XLH Registry will be publicly available and published in
peer-reviewed journals. In addition, as the XLH Registry
is registered on ClinicalTrials.gov, with full information
accessibility publicly available, suitably qualified individ-
uals can request access to the registry for research pur-
poses. This approach meets the interoperability and
reuse components of the FAIR principles [32].
Conclusion
This observational XLH patient registry aims to recruit
1200 patients with XLH, over 10 years. It has been
designed to further the clinical understanding of this
chronic, progressive and debilitating genetic disease. It
also aims to categorise the demographics, natural histor-
ies and treatment histories of both paediatric and adult
patients suffering with XLH. The end goal of this regis-
try is the synthesis, publication and dissemination of
real-world evidence from the collected data, which can
be used to improve both the understanding and clinical
management of XLH.
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